(0.22%) 5 029.65 points
(0.32%) 38 023 points
(0.39%) 15 667 points
(0.04%) $79.03
(3.78%) $2.01
(-0.56%) $2 298.10
(0.22%) $26.81
(0.40%) $958.75
(0.31%) $0.936
(0.40%) $11.07
(0.30%) $0.801
(-1.21%) $92.13
Live Chart Being Loaded With Signals
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia...
Stats | |
---|---|
Šios dienos apimtis | 4 337.00 |
Vidutinė apimtis | 34 619.00 |
Rinkos kapitalizacija | 6.85M |
EPS | $0 ( 2024-04-02 ) |
Kita pelno data | ( $-2.20 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.230 |
ATR14 | $0.0810 (2.98%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | King Thomas Braxton | Buy | 3 110 | Restricted stock units |
2024-04-18 | Patane Michael A | Buy | 3 556 | Restricted stock units |
2024-04-18 | Lee Catherine Chai-zon | Buy | 3 556 | Restricted stock units |
2024-04-18 | Mills Robert S | Buy | 4 667 | Restricted stock units |
2024-04-18 | Roberts Brandi | Buy | 5 333 | Restricted stock units |
INSIDER POWER |
---|
71.16 |
Last 95 transactions |
Buy: 4 806 950 | Sell: 2 066 322 |
Tūris Koreliacija
TFF Pharmaceuticals Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MRACW | 0.954 |
BIOL | 0.949 |
NRBO | 0.946 |
RMRM | 0.942 |
KBSF | 0.94 |
SLNH | 0.939 |
GRNV | 0.935 |
AVCT | 0.934 |
AYLA | 0.929 |
TDAC | 0.927 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
VLYPO | -0.938 |
BOCH | -0.931 |
IART | -0.923 |
SLGN | -0.92 |
MMAC | -0.919 |
RFEU | -0.919 |
LMRK | -0.918 |
INNV | -0.917 |
LOPE | -0.914 |
AGFS | -0.911 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
TFF Pharmaceuticals Inc Koreliacija - Valiuta/Žaliavos
TFF Pharmaceuticals Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $733 871 |
Bruto pelnas: | $231 391 (31.53 %) |
EPS: | $-11.85 |
FY | 2023 |
Pajamos: | $733 871 |
Bruto pelnas: | $231 391 (31.53 %) |
EPS: | $-11.85 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-388 221 (0.00 %) |
EPS: | $-26.49 |
FY | 2021 |
Pajamos: | $88.00 |
Bruto pelnas: | $88.16 (100.00 %) |
EPS: | $-0.00152 |
Financial Reports:
No articles found.
TFF Pharmaceuticals Inc
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.